Business Description
BeyondSpring Inc
NAICS : 325411
SIC : 2833
28 Liberty Street, 39th Floor, New York, NY, USA, 10005
Description
BeyondSpring Inc is engaged in clinical stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. The Company has created Plinabulin which is marine derived small-molecule with a number of distinct biological activities that may provide multiple therapeutic opportunities. Plinabulin has increased the survival of neutrophils, a type of white blood cell important in the prevention of bacterial infections. The Company has a scalable business model integrating clinical resources in the United States and China.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 20.24 | |||||
| Equity-to-Asset | 0.33 | |||||
| Debt-to-Equity | 0.13 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -6.99 | |||||
| Beneish M-Score | 2.77 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 13.3 | |||||
| 3-Year EPS without NRI Growth Rate | 12.2 | |||||
| 3-Year FCF Growth Rate | 10.2 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 74.31 | |||||
| 9-Day RSI | 59.89 | |||||
| 14-Day RSI | 54.1 | |||||
| 6-1 Month Momentum % | -41.04 | |||||
| 12-1 Month Momentum % | -93.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.96 | |||||
| Quick Ratio | 4.96 | |||||
| Cash Ratio | 4.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -4903.03 | |||||
| Net Margin % | -4750.48 | |||||
| ROE % | -114.13 | |||||
| ROA % | -67.32 | |||||
| ROIC % | -743.2 | |||||
| ROC (Joel Greenblatt) % | -2610.86 | |||||
| ROCE % | -80.69 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 38.6 | |||||
| PB Ratio | 2.04 | |||||
| Price-to-Tangible-Book | 2.01 | |||||
| EV-to-EBIT | 0.24 | |||||
| EV-to-Forward-EBIT | -0.04 | |||||
| EV-to-EBITDA | 0.24 | |||||
| EV-to-Forward-EBITDA | -0.04 | |||||
| EV-to-Revenue | -10.69 | |||||
| EV-to-Forward-Revenue | 1.19 | |||||
| EV-to-FCF | 0.19 | |||||
| Price-to-Net-Current-Asset-Value | 2.67 | |||||
| Price-to-Net-Cash | 3.09 | |||||
| Earnings Yield (Greenblatt) % | 433.28 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:BYSI
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.351 | ||
| EPS (TTM) ($) | -1.64 | ||
| Beta | 0.93 | ||
| Volatility % | 259.77 | ||
| 14-Day RSI | 54.1 | ||
| 14-Day ATR ($) | 0.131918 | ||
| 20-Day SMA ($) | 1.454 | ||
| 12-1 Month Momentum % | -93.26 | ||
| 52-Week Range ($) | 1.13 - 33 | ||
| Shares Outstanding (Mil) | 38.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BeyondSpring Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||